DK39892D0 - Peptid - Google Patents

Peptid

Info

Publication number
DK39892D0
DK39892D0 DK92398A DK39892A DK39892D0 DK 39892 D0 DK39892 D0 DK 39892D0 DK 92398 A DK92398 A DK 92398A DK 39892 A DK39892 A DK 39892A DK 39892 D0 DK39892 D0 DK 39892D0
Authority
DK
Denmark
Prior art keywords
glp
pct
agonists
receptor
sec
Prior art date
Application number
DK92398A
Other languages
English (en)
Inventor
Bernard Thorens
Original Assignee
Bernard Thorens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093079&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK39892(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bernard Thorens filed Critical Bernard Thorens
Priority to DK92398A priority Critical patent/DK39892D0/da
Publication of DK39892D0 publication Critical patent/DK39892D0/da
Priority to US08/142,439 priority patent/US5670360A/en
Priority to DE69326405T priority patent/DE69326405T2/de
Priority to JP51628793A priority patent/JP3371379B2/ja
Priority to EP93906589A priority patent/EP0586657B1/en
Priority to ES93906589T priority patent/ES2070801T1/es
Priority to PCT/EP1993/000697 priority patent/WO1993019175A1/en
Priority to AT93906589T priority patent/ATE184648T1/de
Priority to AU37512/93A priority patent/AU3751293A/en
Priority to DE0586657T priority patent/DE586657T1/de
Priority to GR950300031T priority patent/GR950300031T1/el
Priority to US08/869,477 priority patent/US5846747A/en
Priority to US08/935,317 priority patent/US6051689A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/605—Glucagons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK92398A 1992-03-25 1992-03-25 Peptid DK39892D0 (da)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DK92398A DK39892D0 (da) 1992-03-25 1992-03-25 Peptid
DE0586657T DE586657T1 (de) 1992-03-25 1993-03-23 Receptor für das Glucagon ähnliches Peptid-1 (GLP-1).
AU37512/93A AU3751293A (en) 1992-03-25 1993-03-23 Receptor for the glucagon-like-peptide-1 (GLP-1)
ES93906589T ES2070801T1 (es) 1992-03-25 1993-03-23 Receptor para el peptido-1 similar al glucagon (glp-1).
DE69326405T DE69326405T2 (de) 1992-03-25 1993-03-23 Receptor für das Glucagon ähnliches Peptid-1 (GLP-1)
JP51628793A JP3371379B2 (ja) 1992-03-25 1993-03-23 グルカゴン様ペプチド−１（ｇｌｐ−１）に対するレセプター
EP93906589A EP0586657B1 (en) 1992-03-25 1993-03-23 Receptor for the glucagon-like-peptide-1 (glp-1)
US08/142,439 US5670360A (en) 1992-03-25 1993-03-23 Mammalian receptors for glucagon-like-peptide-1 (GLP-1), corresponding DNA and recombinant expression systems, and screening assays for GLP-1 agonists and enhancers
PCT/EP1993/000697 WO1993019175A1 (en) 1992-03-25 1993-03-23 Receptor for the glucagon-like-peptide-1 (glp-1)
AT93906589T ATE184648T1 (de) 1992-03-25 1993-03-23 Receptor für das glucagon ähnliches peptid-1 (glp-1)
GR950300031T GR950300031T1 (en) 1992-03-25 1995-06-30 Receptor for the glucagon-like-peptide-1 (glp-1).
US08/869,477 US5846747A (en) 1992-03-25 1997-06-05 Method for detecting glucagon-like peptide-1 antagonists and agonists
US08/935,317 US6051689A (en) 1992-03-25 1997-09-22 Receptor for the glucagon-like-peptide (GLP-1)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92398A DK39892D0 (da) 1992-03-25 1992-03-25 Peptid

Publications (1)

Publication Number Publication Date
DK39892D0 true DK39892D0 (da) 1992-03-25

Family

ID=8093079

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92398A DK39892D0 (da) 1992-03-25 1992-03-25 Peptid

Country Status (10)

Country Link
US (2) US5670360A (da)
EP (1) EP0586657B1 (da)
JP (1) JP3371379B2 (da)
AT (1) ATE184648T1 (da)
AU (1) AU3751293A (da)
DE (2) DE586657T1 (da)
DK (1) DK39892D0 (da)
ES (1) ES2070801T1 (da)
GR (1) GR950300031T1 (da)
WO (1) WO1993019175A1 (da)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
SK155694A3 (en) * 1992-06-15 1995-05-10 Pfizer Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
WO1994005789A1 (en) * 1992-08-28 1994-03-17 Zymogenetics, Inc. Glucagon receptors
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
WO1995004821A1 (en) * 1993-08-09 1995-02-16 Merck & Co., Inc. Human glucagon-like 1 peptide receptor
GB9502830D0 (en) * 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells
US8592553B2 (en) 1996-12-13 2013-11-26 Nps Pharmaceuticals, Inc. Cloned glucagon-like peptide-2 receptors
DK0946591T3 (da) * 1996-12-13 2007-08-13 Nps Allelix Corp Klonede glucagon-lignende peptid-2 receptorer
WO2000007617A1 (en) 1998-07-31 2000-02-17 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
JP2002528721A (ja) * 1998-10-23 2002-09-03 グラクソ グループ リミテッド 核内受容体のリガンド用のアッセイ
JP2003525908A (ja) 2000-03-08 2003-09-02 ノボ ノルディスク アクティーゼルスカブ 血清脂質の低下
US6448045B1 (en) * 2000-03-10 2002-09-10 The Regents Of The University Of California Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1
US20020123071A1 (en) * 2000-12-04 2002-09-05 Knudsen Sanne Moller Method of identifying compounds capable of acting as agonists or antagonists of G-protein coupled receptors
US6642003B2 (en) 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
US6911324B2 (en) * 2001-10-18 2005-06-28 The Regents Of The University Of California Induction of beta cell differentiation in human cells
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7141240B2 (en) * 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
RU2376314C2 (ru) * 2002-10-02 2009-12-20 Зилэнд Фарма А/С Стабилизированные соединения эксендина-4
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2004071393A2 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
WO2005018536A2 (en) * 2003-05-23 2005-03-03 Human Genome Sciences, Inc. Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
DK1687019T3 (da) 2003-11-20 2018-02-12 Novo Nordisk As Propylengykol peptidformuleringer som er optimale til produktion og anvendelse i injektionsanordninger
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
SG156683A1 (en) 2005-06-07 2009-11-26 Univ Rockefeller STIMULATION OF PANCREATIC β CELL PROLIFERATION
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US8718994B2 (en) * 2008-04-09 2014-05-06 Transtech Pharma, Llc Ligands for the GLP-1 receptor and methods for discovery thereof
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
NZ603169A (en) 2010-04-27 2015-02-27 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (pt) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Acelerómetro pendular
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
US20150038417A1 (en) 2011-12-09 2015-02-05 Novo Nordisk A/S GLP-1 Agonists
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
RS64942B1 (sr) 2012-03-22 2024-01-31 Novo Nordisk As Kompozicije koje obuhvataju sredstvo za isporuku i njihova priprema
AU2013286177B2 (en) 2012-07-01 2018-04-26 Novo Nordisk A/S Use of long-acting GLP-1 peptides
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP2016500682A (ja) 2012-10-17 2016-01-14 ノヴォ ノルディスク アー／エス 経口ペプチドデリバリーのための脂肪酸アシル化アミノ酸
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
AU2015205620A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin aspart
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CA2965732A1 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
EP3359181A1 (en) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
EP3773475A1 (en) 2018-04-06 2021-02-17 Cyprumed GmbH Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
KR20220143037A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 Glp-1 조성물 및 이의 용도
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
JP2023524695A (ja) 2020-04-29 2023-06-13 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬およびヒスチジンを含む固形組成物
JP2023541827A (ja) 2020-09-07 2023-10-04 サイプルメド ゲーエムベーハー Ｇｌｐ－１受容体アゴニストの改善された医薬製剤
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) * 1992-03-25 1992-03-25 Bernard Thorens Peptid

Also Published As

Publication number Publication date
GR950300031T1 (en) 1995-06-30
JP3371379B2 (ja) 2003-01-27
WO1993019175A1 (en) 1993-09-30
DE586657T1 (de) 1996-01-18
EP0586657B1 (en) 1999-09-15
US6051689A (en) 2000-04-18
EP0586657A1 (en) 1994-03-16
AU3751293A (en) 1993-10-21
DE69326405D1 (de) 1999-10-21
DE69326405T2 (de) 2000-03-23
ES2070801T1 (es) 1995-06-16
JPH06508765A (ja) 1994-10-06
US5670360A (en) 1997-09-23
ATE184648T1 (de) 1999-10-15

Similar Documents

Publication Publication Date Title
DK39892D0 (da) Peptid
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
ATE193541T1 (de) Insulinotropes hormon
DK0758383T3 (da) Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
IL112112A (en) Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
IL103750A0 (en) Bacillus promoter
DE69327309D1 (de) Verwendung eines peptids
DK0675956T3 (da) Nyt protein fra urin betegnet komponent B
DE69323765D1 (de) Säugetier-rezeptoren für interleukin 10 (il-10)
ATE184022T1 (de) Neuropeptide y antagoniste
ATE106943T1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
DE60133271D1 (de) Behandlung von knorpelerkrankungen
DK0637334T3 (da) Peptider med en GDP-udskiftningsfaktoraktivitet, nukleinsyresekvenser, der koder for disse peptider, fremstilling og anvendelse
NO951689L (no) DNA som koder for en human serotoninreseptor (5-HT4B) og anvendelse av denne
ATE279515T1 (de) Pct-65 serotonin rezeptor
DK0652964T3 (da) Promotor af K. lactis transaldolasegenet og anvendelse heraf
DK0773999T3 (da) OR-1, en orphan-receptor tilhørende kernereceptorfamilien
HUT68067A (en) Expression signal-peptide-free staphylokinases
DE69133340D1 (de) Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen
DE69737561D1 (de) Klonierte rezeptoren des glukagon-ähnlichen peptids-2
FR2693200B1 (fr) Nouveaux polypeptides ayant une activité de récepteur sérotoninergique, acides nucléiques codant pour ces polypeptides et utilisations.
ES2059801T3 (es) Nuevas linfoquinas, secuencias de adn que codifican para estas linfoquinas, y composiciones farmaceuticas conteniendo estas linfoquinas.
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment